T
Trent R. Gemmill
Researcher at State University of New York System
Publications - 5
Citations - 215
Trent R. Gemmill is an academic researcher from State University of New York System. The author has contributed to research in topics: Heparan sulfate & Heparin. The author has an hindex of 5, co-authored 5 publications receiving 204 citations. Previous affiliations of Trent R. Gemmill include New York State Department of Health & Albany College of Pharmacy and Health Sciences.
Papers
More filters
Journal ArticleDOI
The Ess1 prolyl isomerase is required for transcription termination of small noncoding RNAs via the Nrd1 pathway.
Navjot Singh,Zhuo Ma,Trent R. Gemmill,Trent R. Gemmill,Xiaoyun Wu,Xiaoyun Wu,Holland DeFiglio,Anne Rossettini,Christina Rabeler,Olivia Beane,Randall H. Morse,Randall H. Morse,Michael J. Palumbo,Steven D. Hanes,Steven D. Hanes +14 more
TL;DR: It is shown that the prolyl isomerase Ess1 is required for Nrd1-dependent termination of noncoding RNAs and evidence is provided for a competition between Nrd 1 and Pcf11 for CTD binding that is regulated by Ess1.
Journal ArticleDOI
Vanishingly Low Levels of Ess1 Prolyl-isomerase Activity Are Sufficient for Growth in Saccharomyces cerevisiae
TL;DR: Describing wild-type and mutant Ess1 proteins in vitro and in vivo found that Ess1 preferentially binds and isomerizes CTD heptad-repeat (YSPTSPS) peptides that are phosphorylated on Ser5, suggesting that Ess 1 is important for tolerance to environmental challenge.
Journal ArticleDOI
Bioengineered Chinese Hamster Ovary Cells with Golgi-targeted 3-O-Sulfotransferase-1 Biosynthesize Heparan Sulfate with an Antithrombin-binding Site
Payel Datta,Guoyun Li,Guoyun Li,Bo Yang,Xue Zhao,Jong Youn Baik,Trent R. Gemmill,Susan T. Sharfstein,Robert J. Linhardt +8 more
TL;DR: It is demonstrated that untargeted HS3st1 is broadly distributed throughout CHO cells and forms no detectable AT-binding sites, whereas Golgi-targeted HS 3st1 localizes in the Golgi and results in the formation of a single type of AT- binding site and high anti-factor Xa activity.
Journal ArticleDOI
Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin
Jong Youn Baik,Hussain Dahodwala,Eziafa I. Oduah,Lee Talman,Trent R. Gemmill,Trent R. Gemmill,Leyla Gasimli,Payel Datta,Bo Yang,Guoyun Li,Fuming Zhang,Lingyun Li,Robert J. Linhardt,Andrew M. Campbell,Stephen F. Gorfien,Susan T. Sharfstein +15 more
TL;DR: Bioprocess optimization, in parallel with metabolic engineering refinements, will play a substantial role in developing a bioengineered heparin to replace the current animal-derived drug.
Journal ArticleDOI
Bioengineering murine mastocytoma cells to produce anticoagulant heparin.
Leyla Gasimli,Charles A. Glass,Payel Datta,Bo Yang,Guoyun Li,Trent R. Gemmill,Jong Youn Baik,Susan T. Sharfstein,Jeffrey D. Esko,Robert J. Linhardt,Robert J. Linhardt +10 more
TL;DR: It is shown that transfection of MST cells with a retroviral vector containing heparan sulfate 3-O-sulfotransferase-1 (Hs3st1) restores anticoagulant activity and contributes toward a better understanding of the HP biosynthetic pathway.